23 results about "Synovial Cell" patented technology

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.

The application provides a pharmaceutical composition for treating rheumatoid arthritis, which is composed of paeoniflorin, glycyrrhizin, glycyrrhizic acid and glycyrrhetic acid in a weight ratio of (4.5-7.5):(0.4-1.8):(1.8-4.3):(22-40). The pharmaceutical composition can significantly inhibit the proliferation of fibroblast-like synoviocytes, reduce the secretion of inflammation-related factors (TNF-alpha, IL-1beta, IL-6 and COX-2), regulate the expression of TNF-alpha / NF-kappaB signal pathway-related proteins, and has a significant curative effect on rheumatoid arthritis.

This invention relates to the field of pharmaceutical formulation and preparation and application technology, and particularly to a biomimetic carrier-free nanoparticle with synergistic effects of copper death and chemokinetics, its preparation method, and its application. The nanoparticle is constructed with a metallophenol network formed by the coordination self-assembly of gallic acid and copper ions, and coated with a neutrophil membrane. Copper ions can catalyze the generation of hydroxyl radicals from hydrogen peroxide through a Fenton-like reaction, inducing copper death in diseased synovial cells, thereby efficiently clearing inflammatory cells. Gallic acid exerts anti-inflammatory and antioxidant effects, synergistically regulating the inflammatory microenvironment. The neutrophil membrane endows the nanoparticle with the ability to actively target inflamed joints, effectively reducing off-target toxicity. The nanoparticles provided by this invention have advantages such as strong targeting, high biocompatibility, simple preparation, and a clear synergistic therapeutic mechanism, which can significantly improve the therapeutic effect of rheumatoid arthritis and reduce systemic toxic side effects.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a soluble epoxide hydrolase inhibitor, a pharmaceutical composition, a pharmaceutical preparation and application of the soluble epoxide hydrolase inhibitor in rheumatoid arthritis drugs. The invention provides a soluble epoxide hydrolase inhibitor which is a compound shown in a formula (I) or a tautomer, a stereoisomer, a hydrate, a solvate, a crystal form, a pharmaceutically acceptable salt or a prodrug thereof, and substituent groups R1-R23 are defined in the text. The soluble epoxide hydrolase inhibitor provided by the invention can remarkably inhibit proliferation, migration and invasion of fibroblast-like synovial cells, promote apoptosis of the fibroblast-like synovial cells and relieve the symptoms of rheumatoid arthritis, has relatively low side effects, and can prolong the half-life period of a drug in vivo.

The invention discloses an application of green tendon relaxing ketone in preparation of a medicine for treating rheumatoid diseases. The invention proposes and verifies that the green tendon relaxing ketone can effectively promote fibroblast-like synovial cell ferroptosis so as to inhibit synovial hyperplasia and inhibit the expression of proinflammatory cytokines so as to effectively relieve the progress of rheumatoid arthritis for the first time, and has an excellent application prospect in clinical treatment of rheumatoid diseases.

The disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene within synovial cells is regulated by an inflammation-sensitive promoter.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

The application belongs to the technical field of biological medicine, and discloses application of oridonin in preparation of a medicine for treating rheumatoid arthritis synovitis. For the first time, it is confirmed that oridonin takes glyceraldehyde-3-phosphate dehydrogenase as a direct action target, covalently combines through an α, β-unsaturated ketone, inhibits enzyme activity, blocks abnormal glycolysis of rheumatoid arthritis synovial cells, activates a KEAP1-NRF2 / HO-1 antioxidant anti-inflammatory pathway, inhibits an NF-κB inflammatory signal, and intervenes in a pathological process of rheumatoid arthritis synovitis from multiple dimensions, thereby providing a scientific basis for clinical application and deep development of oridonin against RA synovitis. A medicine composition containing oridonin and application of the medicine composition in preparation of an anti-rheumatoid arthritis synovitis medicine are disclosed. The application has advantages of target point precision, remarkable curative effect, high safety, mechanism innovation and the like, and provides a brand-new scheme for clinical treatment of rheumatoid arthritis synovitis.

The application provides application of SEMA3E protein in preparation of a drug for treating rheumatoid arthritis and promoting cartilage regeneration, and belongs to the technical field of biological medicine. The amino acid sequence of the SEMA3E protein is shown as SEQ ID No. 1. Research results show that one month after injection of the SEMA3E protein solution, the joint swelling degree of the double hind limbs of an animal model is reduced, the joint space and integrity are restored to normal, the cartilage thickness is increased, and the phenomenon of synovial cell infiltration and invasion into the cartilage is eliminated. That is, the SEMA3E protein can well reduce joint cavity inflammation and improve damaged joints.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The invention relates to a plant active ingredient for inhibiting synovial cell inflammatory response and a method for treating rheumatoid arthritis by using the plant active ingredient. The active ingredient is selected from one or more of kaempferide, quercetin, luteolin and alpinetin sesquiterpenoids, and is derived from medicinal plants such as alpinia pumila, glabrous sarcandra herb or herba epimedii and the like. The high-purity flavonoid monomer is obtained through a specific extraction process including ethanol reflux extraction, ethyl acetate extraction, macroporous resin enrichment and silica gel column chromatography separation. The composition can remarkably inhibit activation of NF-kappa B signal channels in synovial cells in vitro, reduce expression levels of inflammatory factors TNF-alpha, IL-1beta and IL-6 and reduce generation of reactive oxygen species (ROS) and nitric oxide (NO), and has a good anti-rheumatic arthritis effect. The active component can be prepared into various dosage forms such as capsules, granules, injections and the like, and is suitable for treatment or adjuvant treatment of rheumatic arthritis and related diseases thereof.

The application belongs to the technical field of medicine, and discloses application of a sesquiterpenoid compound in preparation of a drug for regulating synovial cells. The application first discloses a triple regulation mechanism of CJB on fibroblast-like synovial cells, i.e. inhibiting cell proliferation, reducing inflammatory reaction, and regulating ferroptosis pathway. Compared with a single-target drug, the multi-target effect mode can more comprehensively control the pathological process of RA, not only inhibits abnormal proliferation of FLS and secretion of inflammatory factors, but also removes pathological synovial cells by regulating ferroptosis and apoptosis, significantly improves the treatment effect, and reduces disease recurrence. Moreover, CJB has low toxicity, raw materials are easy to obtain, and can be used in combination with existing anti-rheumatic drugs, thereby reducing drug side effects and treatment costs.

The application relates to an engineered exosome and a preparation method and application thereof, wherein the engineered exosome comprises a natural exosome, a photosensitizer and miR451a loaded in the natural exosome, and an anti-FAP alpha antibody or an antibody fragment loaded on the surface of the natural exosome; the anti-FAP alpha antibody is used for guiding the target receptor cell of the engineered exosome to be combined; the photosensitizer and the miR451a participate in the occurrence of ferroptosis of the target receptor cell under the action of photodynamic effect; and the target receptor cell is an activated fibroblast-like synoviocyte in rheumatic lesions. The application has the beneficial effects of providing a synergistic scheme of "biological carrier + physical stimulation" for RA treatment and having the treatment characteristics of high efficiency, low toxicity and high targeting.

A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.

The invention discloses application of a D-dopa pigment isomerase inhibitor in preparation of a medicine for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. The invention defines that D-DT is an independent and key driving factor for rheumatoid arthritis, especially for the pathological behavior of fibroblast-like synovial cells. The specific molecular mechanism that D-DT plays a role in FLS through an MAPK signal path-COX-2 / PGE2 signal axis is systematically clarified for the first time, and a complete'target spot-pathway-function 'chain is formed. In-vitro and in-vivo experiments prove that selective inhibition of D-DT can effectively relieve disease symptoms and pathological progression, and solid principle verification is provided for development of a new therapy.

The invention discloses a giantleaf ardisia rhizome leaf extract, a preparation method thereof and application of the giantleaf ardisia rhizome leaf extract in preparation of medicines for preventing and treating gouty arthritis. The method comprises the following steps: extracting leaves of giantleaf ardisia rhizome with ethanol or an ethanol aqueous solution, dissolving an extract in water, and extracting with n-hexane and ethyl acetate in sequence to obtain an ethyl acetate extract, namely the giantleaf ardisia rhizome leaf extract. The treatment potential of the AK leaves on gouty arthritis is systematically evaluated for the first time, and it is found that the ethyl acetate component (EF) of the AK leaves has the remarkable effects of resisting inflammation, relieving synovial cell apoptosis and protecting cartilage. Through network pharmacological analysis, the AK is identified to have a multi-target and multi-channel anti-inflammatory mechanism. The medicinal value of the AK leaves is disclosed, a new normal form is provided for sustainable utilization of wild medicinal plants, and the dual innovative significance of ecological protection and drug development is considered.

This invention discloses an inflammatory pretreatment xenogeneic synovial cell-derived vesicle, its preparation method, and its application in the treatment of osteoarthritis, belonging to the field of biomedical technology. The preparation method includes: obtaining and culturing rabbit synovial fibroblast-like cells; subjecting the cells to inflammatory pretreatment for 40-60 hours using a culture medium containing 70-80 ng / mL tumor necrosis factor-α (TNF-α); collecting the cell supernatant, and purifying it by differential centrifugation and ultracentrifugation to obtain the vesicles. The vesicles have a particle size distribution of 100-1000 nm, with a higher proportion of larger particles (>800 nm) than natural vesicles. This invention also provides a pharmaceutical composition containing these vesicles and their application in the preparation of drugs for treating osteoarthritis. Experiments show that these vesicles can significantly inhibit subchondral ossification and osteophyte formation, effectively protect articular cartilage, and have a therapeutic effect superior to natural vesicles, providing a novel cell-free therapeutic strategy for osteoarthritis.

The invention belongs to the technical field of synthesis of natural products, and provides a quassin derivative, a preparation method of the quassin derivative and application of the quassin derivative to treatment of rheumatoid arthritis, and the quassin derivative has a structure shown in the specification. In a cell test experiment of the synthesized compound, it is found for the first time that the compound has remarkable inhibitory activity on fibroblast-like synovial cells, so that the compound has potential application prospects in preparation of drugs for preventing and / or treating rheumatoid arthritis.

A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts.

The invention relates to the technical field of medicines, in particular to application of mulberry total flavonoids in preparation of a preparation for treating rheumatoid arthritis. The medicine mulberry total flavonoids have definite anti-inflammatory and protective effects on the histology level. After intervention of the medicine mulberry general flavone, the autophagy function of the synovial cells can be recovered. The medicine mulberry general flavone can also be used for synchronously down-regulating the expression of p-PI3K, p-AKT and p-mTOR, up-regulating Beclin-1 and LC3-II, and remarkably reducing the levels of TNF-alpha, IL-6 and IL-17 in serum. Therefore, the medicine mulberry general flavone can restore autophagy activity and relieve synovitis and joint injury by inhibiting a PI3K / AKT / mTOR axis.

The application discloses an alkaloid compound and a preparation method and application thereof, and extracts the alkaloid compound from Mallotus apelta. The new alkaloid compound is extracted from Mallotus apelta, has a good inhibiting effect on synovial cells, has a good anti-rheumatoid arthritis effect, and can be used for preparing anti-rheumatoid arthritis drugs.

The invention is applicable to the technical field of traditional Chinese medicine powder for treating arthralgia and provides traditional Chinese medicine powder for treating arthralgia and a preparation method thereof, and the traditional Chinese medicine powder for treating arthralgia comprises the following substances in parts by mass: 8-12 parts of tripterygium wilfordii, 4-6 parts of ligusticum wallichii, 8-12 parts of salvia miltiorrhiza, 1.6-2.4 parts of mirabilite and 4-6 parts of rheum officinale. According to the traditional Chinese medicine steeping powder for treating arthralgia and the preparation method of the traditional Chinese medicine steeping powder, the traditional Chinese medicine steeping powder takes four mechanisms of immunoregulation, anti-inflammation, blood circulation activation and detumescence as a core, accurate strike on the pathological link of rheumatoid arthritis is formed, triptolide in tripterygium wilfordii can inhibit T cell overactivity and block the start of autoimmune response, and the curative effect is good. Ligustrazine improves joint local microcirculation disturbance by expanding microvessels and inhibiting platelet aggregation, tanshinone has a strong anti-oxidation effect and can remove excessive oxygen free radicals generated in the inflammation process and relieve synovial cell damage, and sodium sulfate in mirabilite can promote absorption of inflammatory exudates in articular cavities and relieve swelling.